Equities research analysts at Truist Financial initiated coverage on shares of OmniAb (NASDAQ:OABI – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set a "buy" rating and a $10.00 price target on the stock. Truist Financial's target price would indicate a potential upside of 159.07% from the stock's current price.
Several other equities research analysts have also recently issued reports on OABI. Credit Suisse Group started coverage on shares of OmniAb in a research note on Friday, December 16th. They set an "outperform" rating and a $13.00 price target on the stock. SVB Leerink started coverage on shares of OmniAb in a research report on Tuesday, November 29th. They issued an "outperform" rating and a $6.00 target price on the stock. Finally, Stifel Nicolaus started coverage on shares of OmniAb in a research report on Monday, November 28th. They issued a "buy" rating and a $12.00 target price on the stock.
Get
OmniAb alerts:
OmniAb Trading Up 17.0 %
OmniAb stock opened at $3.86 on Tuesday. OmniAb has a 12-month low of $1.91 and a 12-month high of $10.50.
Insider Activity
In other news, CEO Matthew W. Foehr acquired 300,000 shares of the company's stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $3.39 per share, for a total transaction of $1,017,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,705,350 shares of the company's stock, valued at approximately $5,781,136.50. The transaction was disclosed in a filing with the SEC, which is available at
this hyperlink. In other news, CEO Matthew W. Foehr acquired 300,000 shares of the company's stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $3.39 per share, for a total transaction of $1,017,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,705,350 shares of the company's stock, valued at approximately $5,781,136.50. The transaction was disclosed in a filing with the SEC, which is available at
this hyperlink. Also, CEO Matthew W. Foehr purchased 150,000 shares of the company's stock in a transaction that occurred on Monday, December 12th. The stock was bought at an average price of $3.77 per share, with a total value of $565,500.00. Following the purchase, the chief executive officer now owns 1,838,084 shares of the company's stock, valued at approximately $6,929,576.68. The disclosure for this purchase can be found
here. Insiders have bought 482,250 shares of company stock worth $1,694,038 over the last 90 days.
About OmniAb
(Get Rating)
OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
Featured Stories
- Get a free copy of the StockNews.com research report on OmniAb (OABI)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
